touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer.
The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer (NCT04752332)’ (abstract number TPS596) was presented at the 2021 ASCO Annual Meeting.
Questions
- What are the current unmet needs in the treatment of patients with HR+, HER2+ breast cancer with high-risk characteristics? (0:17–0:52)
- What is known about the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in this patient population? (1:01–2:59)
- What are the aims, design and inclusion criteria of the eMonarcHER trial? (3:04–4:18)
- What are the primary and key secondary endpoints of the study, and when are data expected? (4:24–5:03)
- What other trials are ongoing to address recurrence in advanced early-stage HER2+ disease? (5:09–6:01)
Disclosures: Dr Sara Tolaney has no financial or non-financial relationships or activities to declare in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
References
- ClinicalTrials.gov. A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER). ClinicalTrials.gov Identifier: NCT04752332. Available at: https://clinicaltrials.gov/ct2/show/NCT04752332 (accessed 8 June 2021).
- Tolaney SM, Fallowfield L, Kaufman PA, et al. eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer. J Clin Oncol. 2021;39(Suppl. 15): Abstr TPS596.
CDK4/6 = cyclin-dependent kinase 4 and 6; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor.
